Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies, Neurology, Psychiatric, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 6/20/2018 |
| Start Date: | October 2013 |
| End Date: | February 2017 |
Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study
The goal of this research is to understand the functioning of 'regulatory circuits' in the
brain. We are also interested in how the medications methylphenidate and naltrexone affect
these regulatory circuits. This research study will use a scanning technique known as
functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the
brain that enables us to "see the brain at work". Adult participants will be given a one-time
dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session.
The main purpose for this research is to better understand the functioning of regulatory
circuits in healthy individuals and individuals with psychiatric disorders. This research may
one day help us develop better treatments for these disorders.
brain. We are also interested in how the medications methylphenidate and naltrexone affect
these regulatory circuits. This research study will use a scanning technique known as
functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the
brain that enables us to "see the brain at work". Adult participants will be given a one-time
dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session.
The main purpose for this research is to better understand the functioning of regulatory
circuits in healthy individuals and individuals with psychiatric disorders. This research may
one day help us develop better treatments for these disorders.
The goal of this research is to understand the functioning of 'regulatory circuits' in the
brain. These are brain circuits which allow a person to regulate their attention, regulate
their behavioral responses, and regulate their decision-making. We are also interested in how
the medications methylphenidate and naltrexone affect these regulatory circuits.
Methylphenidate is a widely-used, FDA approved medication used to treat Attention Deficit
Hyperactivity Disorder (ADHD) and is also known as Ritalin. Naltrexone is an FDA approved
medication used to help treat alcohol and substance abuse.
This research study will use a scanning technique known as functional magnetic resonance
imaging (fMRI)which takes a special kind of picture of the brain that enables us to "see the
brain at work". Adult participants will be given a one-time dose of either methylphenidate,
naltrexone,or placebo before each fMRI scan session. There are three total fMRI scan
sessions. Therefore, each participant will receive each possible medication/placebo only
once.
Using the fMRI technique, the main purpose of this research is to better understand the
functioning of regulatory circuits in healthy individuals and individuals with psychiatric
disorders. This research may one day help us develop better treatments for these disorders.
brain. These are brain circuits which allow a person to regulate their attention, regulate
their behavioral responses, and regulate their decision-making. We are also interested in how
the medications methylphenidate and naltrexone affect these regulatory circuits.
Methylphenidate is a widely-used, FDA approved medication used to treat Attention Deficit
Hyperactivity Disorder (ADHD) and is also known as Ritalin. Naltrexone is an FDA approved
medication used to help treat alcohol and substance abuse.
This research study will use a scanning technique known as functional magnetic resonance
imaging (fMRI)which takes a special kind of picture of the brain that enables us to "see the
brain at work". Adult participants will be given a one-time dose of either methylphenidate,
naltrexone,or placebo before each fMRI scan session. There are three total fMRI scan
sessions. Therefore, each participant will receive each possible medication/placebo only
once.
Using the fMRI technique, the main purpose of this research is to better understand the
functioning of regulatory circuits in healthy individuals and individuals with psychiatric
disorders. This research may one day help us develop better treatments for these disorders.
Inclusion Criteria for all study participants:
- Right-Handedness
Exclusion Criteria for all study participants:
- Any clinically significant history of cardiac problems
- Any current Axis I psychiatric diagnosis as verified by the Structured Clinical
Interview for DSM-IV (other than participants with ADHD or history of alcohol
dependence)
- A previous adequate trial with methylphenidate (Ritalin) or naltrexone (ReVia)
- Currently taking any psychoactive medications
- Any clinically significant medical condition
- Any clinically significant neurological problem (seizures, tics, serious head injury)
- Contraindications to MRI (metal objects in body or claustrophobia)
- Currently pregnant or lactating
- Alcohol or substance abuse (current or in the past 2 years)
- Left-handedness or ambidextrous
- Liver or kidney disease
Inclusion Criteria for the participants with ADHD:
- Currently un-medicated adults with ADHD
- Has met full DSM-IV-R criteria (at least six of nine symptoms)for inattentive or
hyperactive/impulsive subtypes (or both) by age 7 as well within the past month
- Has described a chronic course of ADHD symptomatology from childhood to adulthood
- Has endorsed a moderate or severe level of impairment attributed to the ADHD symptoms
We found this trial at
1
site
Ann Arbor, Michigan 48109
Principal Investigator: Chandra Sekhar Sripada, MD, PhD
Phone: 734-232-0353
Click here to add this to my saved trials
